MedTrace Logo

Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

NCT01375023 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2015-06-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the engraftment, toxicity and anti-tumour activity of allogeneic peripheral blood progenitor cell (PBPC) transplantation using TLI/ATG conditioning regimen in patients with refractory "Triple Negative" breast cancer.

Conditions

Interventions

RADIATION

Radiotherapy

daily radiation therapy for 10 days, total dose of 80 cGY

BIOLOGICAL

Anti-Thymocyte Globulin

1.5 mg/kg/day, IV from day -11 through day -7 before transplantation

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    collaborator OTHER

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Rocco Pastano, MD · European Institute of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-07-31
Completion
2013-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01375023 on ClinicalTrials.gov